Advertisement
Screener

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) Material Contracts, 2012

IOVANCE BIOTHERAPEUTICS, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2012-10-04: Form 8-K; Exhibit 10.1; Description FORM OF MATURITY DATE EXTENSION.
  • 2012-07-06: Form 8-K; Exhibit 10.1; Description FORM OF MATURITY DATE EXTENSION.
  • 2012-05-11: Form 8-K; Exhibit 10.2; Description FORM OF SECURED PROMISSORY NOTE, DUE JUNE 30, 2012.
  • 2012-05-11: Form 8-K; Exhibit 10.1; Description FORM OF NOTE AND COMMON STOCK SUBSCRIPTION AGREEMENT.
FiledFormExhibitDescription
2012-10-048-K10.1FORM OF MATURITY DATE EXTENSION
2012-07-068-K10.1FORM OF MATURITY DATE EXTENSION
2012-05-118-K10.2FORM OF SECURED PROMISSORY NOTE, DUE JUNE 30, 2012
2012-05-118-K10.1FORM OF NOTE AND COMMON STOCK SUBSCRIPTION AGREEMENT
2012-04-108-K10.2PROMISSORY NOTE
2012-04-108-K10.1PROMISSORY NOTE
2012-04-058-K10.2FORM OF AMENDMENT NO. 5 TO THE TRANCHE A WARRANTS TO PURCHASE COMMON STOCK AND TRANCHE B WARRANTS TO PURCHASE COMMON STOCK
2012-04-058-K10.1FORM OF AMENDMENT NO. 8 TO TRANCHE A SENIOR UNSECURED CONVERTIBLE NOTES AND TRANCHE B SENIOR UNSECURED CONVERTIBLE NOTES
2012-03-3010-K10.24Manufacturing Service Agreement, dated December __, 2011, by and between Lonza Walkersville and Genesis Biopharma, Inc.
2012-03-3010-K10.14Consulting Agreement dated July 15, 2011, between Bristol and Genesis Biopharma, Inc. Addendum No. 1, dated ____, 2011
2012-03-3010-K10.13Consulting Agreement dated July 15, 2011, between Theorem and Genesis Biopharma, Inc.
2012-03-3010-K10.10Consulting Agreement, dated February 15, 2011, by and between Emmes Group and Genesis Biopharma, Inc., Amendment No. 1, dated ____, 2011, Amendment No. 2, dated February 12, 2012.
2012-03-3010-K10.10BAMENDMENT TO CONSULTING AGREEMENT DATED
2012-03-068-K10.2Form of Amendment No. 4 Tranche A Warrants to Purchase Common Stock and Tranche B Warrants to Purchase Common Stock
2012-03-068-K10.1Form of Amendment No. 6 to Tranche A Senior Unsecured Convertible Notes and Tranche B Senior Unsecured Convertible Notes, effective as of February 29, 2012
2012-02-068-K/A10.1FORM OF AMENDMENT NO. 5 TO TRANCHE A SENIOR UNSECURED CONVERTIBLE NOTES AND TRANCHE B SENIOR UNSECURED CONVERTIBLE NOTES
2012-01-108-K/A10.1

Similar stocks

Stock NameCountryMarket CapPE Ratio
Adaptive Biotechnologies Corp (ADPT)United States$4.719B-53.43
CRISPR Therapeutics AG (CRSP)$5.390B-11.68
Relay Therapeutics, Inc. (RLAY)United States$3.884B-14.30
Scholar Rock Holding Corp (SRRK)United States$5.920B-16.37
CG Oncology, Inc. (CGON)United States$6.095B-27.95
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Immunovant, Inc. (IMVT)United States$7.028B-14.78
Beam Therapeutics Inc. (BEAM)United States$2.549B-41.51
Greenland Mines Ltd (GRML)United States$2.362B